Biogen Paying $5.6B For Apellis As 4 Firms Advise

By Al Barbarino ( March 31, 2026, 5:35 PM EDT) -- Biogen Inc. said Tuesday that it has agreed to acquire Apellis Pharmaceuticals Inc. in a cash transaction valued at about $5.6 billion, with four law firms steering the transaction focused on key therapies for kidney and eye disorders. ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login